New GLP-1R agonists described in MSD patent
Merck Sharp & Dohme LLC (MSD) has disclosed new glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of obesity and type 2 di...
Merck Sharp & Dohme LLC (MSD) has disclosed new glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of obesity and type 2 diabetes.